Nurix Therapeutics, Inc.
11.70-0.20 (-1.68%)
Oct 29, 4:00:01 PM EDT · NasdaqGM · NRIX · USD
Key Stats
Market Cap
1.19BP/E (TTM)
-Basic EPS (TTM)
-2.97Dividend Yield
0%Recent Filings
8-K
Nurix launches CLL trial
Nurix Therapeutics kicked off the DAYBreak Phase 2 trial on October 22, 2025, testing bexobrutideg at 600 mg daily in about 100 triple-exposed relapsed/refractory CLL/SLL patients, aiming for accelerated approval via objective response rate. The dose, cleared by FDA, MHRA, and EMA under Project Optimus, targets unmet needs in heavily pretreated cases. A confirmatory Phase 3 starts H1 2026. NX-1607 showed 49.3% disease control in solid tumors. Clinical success hinges on enrollment and trial outcomes.
8-K
Nurix prices $250M stock offering
Nurix Therapeutics priced its $250 million common stock offering at $10.21 per share, issuing 24,485,799 shares to underwriters led by J.P. Morgan, Jefferies, and Stifel. Net proceeds of approximately $234.3 million will fund clinical development of bexobrutideg in chronic lymphocytic leukemia and autoimmune indications, plus pipeline expansion and general purposes. The deal closes October 23, 2025, subject to conditions. Forward-looking plans hinge on trial outcomes and funding success.
8-K
Q3 results and pipeline advances
Nurix Therapeutics reported Q3 2025 results, posting $7.9 million in revenue, down from $12.6 million last year due to the Sanofi collaboration's research term ending, while R&D expenses surged to $86.1 million from clinical trial acceleration. The company holds $428.8 million in cash, supporting pivotal trials for BTK degrader bexobrutideg in relapsed/refractory CLL starting H2 2025. Preclinical data for IRAK4 degrader GS-6791 with Gilead showed potent efficacy in dermatitis models. Cash burn widened the net loss to $86.4 million.
10-Q
Q3 FY2025 results
Nurix Therapeutics posted Q3 FY2025 collaboration revenue of $7.9M, down 37% y/y from $12.6M as initial research terms with Sanofi and Gilead wrapped up, yet YTD revenue surged 71% to $70.4M on $30M in license fees from Sanofi extensions plus steady Pfizer inflows. R&D costs jumped 55% y/y to $86.1M, driven by accelerated bexobrutideg trials and headcount growth, yielding an operating loss of $91.4M—up 67% y/y—and diluted EPS of -$1.03 on 84.2M shares, consistent with net loss. Cash and marketable securities stood at $428.8M, funding operations through at least the next year amid no debt. Sanofi closed two licenses in March and May 2025 for $15M each (cash), recognizing $30M revenue with no goodwill or intangibles detailed. Substantial competition in protein degradation could erode Nurix's edge if rivals advance faster.
8-K
Bexobrutideg CLL updates
Nurix Therapeutics unveiled clinical updates on bexobrutideg (NX-5948), its oral BTK degrader, showing an 80.9% objective response rate in relapsed/refractory CLL patients from the Phase 1 trial, with robust activity against mutations and CNS involvement. The company plans a pivotal Phase 2 monotherapy in H2 2025 and a Phase 3 confirmatory trial versus standard of care. This positions bexobrutideg to challenge BTK inhibitors in a $15B+ market. Risks include clinical trial uncertainties.
AURX
Nuo Therapeutics, Inc.
2.29+0.00
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
KYMR
Kymera Therapeutics, Inc.
60.03-1.92
NBTX
Nanobiotix S.A.
17.99+0.36
NKTR
Nektar Therapeutics
59.63-1.29
NKTX
Nkarta, Inc.
2.09-0.22
NRXP
NRX Pharmaceuticals, Inc.
3.05+0.05
RAPT
RAPT Therapeutics, Inc.
29.78-0.35
RXRX
Recursion Pharmaceuticals, Inc.
5.87-0.04
TLX
Telix Pharmaceuticals Limited
10.63-0.14